A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection
Current therapy for chronic hepatitis B is suboptimal as a result of limited durable response rates, cumulative viral resistance, and/or poor tolerability. Telbivudine has potent antiviral activity against hepatitis B virus (HBV) in vitro and in the woodchuck model and has a promising preclinical sa...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| 格式: | Artigo |
| 语言: | 英语 |
| 出版: |
2004
|
| 在线阅读: | https://doi.org/10.1002/hep.20374 https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hep.20374 |
| 标签: |
添加标签
没有标签, 成为第一个标记此记录!
|